Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 29, 2009

Recordati Inks Marketing Deals for BPH Therapy in Italy and South Africa

  • Recordati signed new marketing agreements for the benign prostatic hyperplasia (BPH) drug, silodosin, in Italy and South Africa. The deal with Nycomed’s Italian subsidiary covers the co-marketing of silodosin in Italy, and a separate agreement with Pharmaplan gives the South African company exclusive marketing and sales rights in South Africa.

    For the South African market, Pharmaplan will also be responsible for filing an NDA to the country’s regulatory authorities. An MAA for silodosin was submitted to the EMEA in November 2008 and a decision is expected during the first half of 2010.

    Pharmaplan is already Recordati’s South African licensee for the drugs Zanidip® (hypertension), Zaneril® (hypertension), and Lomexin® (vulvovaginal candidiasis).

    Silodosin is an alpha-1 adrenergic receptor antagonist, indicated for the symptomatic treatment of BPH. The drug was originally developed by Kissei in Japan, where it has been marketed as Urief® since 2006. Recordati licensed the drug for Europe and a number of countries in the Middle East and Africa.

    Silodosin was developed in North America by Watson Pharmaceuticals and was approved by the FDA in October 2008. Watson launched the drug as Rapaflo™ in April.


Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »